Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nurix Therapeutics, Inc. (NRIX : NSDQ)
 
 • Company Description   
Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.

Number of Employees: 242

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.98 Daily Weekly Monthly
20 Day Moving Average: 413,389 shares
Shares Outstanding: 44.95 (millions)
Market Capitalization: $448.60 (millions)
Beta: 2.59
52 Week High: $37.43
52 Week Low: $8.40
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -21.48% -11.56%
12 Week -39.15% -33.10%
Year To Date -65.53% -57.88%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1700 OWENS STREET SUITE 205
-
SAN FRANCISCO,CA 94158
USA
ph: 415-660-5320
fax: -
lwolffe@wheelhouselsa.com http://www.nurixtx.com
 
 • General Corporate Information   
Officers
Arthur T. Sands - Chief Executive Officer; President and Director
David L. Lacey - Chairman and Director
Hans van Houte - Chief Financial Officer
Julia P. Gregory - Director
Lori A. Kunkel - Director

Peer Information
Nurix Therapeutics, Inc. (CORR.)
Nurix Therapeutics, Inc. (RSPI)
Nurix Therapeutics, Inc. (CGXP)
Nurix Therapeutics, Inc. (BGEN)
Nurix Therapeutics, Inc. (GTBP)
Nurix Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 67080M103
SIC: 2834
Fiscal Year
Fiscal Year End: November
Last Reported Quarter: 02/01/22
Next Expected EPS Date: 07/12/22
Share - Related Items
Shares Outstanding: 44.95
Most Recent Split Date: (:1)
Beta: 2.59
Market Capitalization: $448.60 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.00 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.92 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/12/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.46
Price/Cash Flow: -
Price / Sales: 13.06
EPS Growth
vs. Year Ago Period: -50.79%
vs. Previous Quarter: -11.76%
Sales Growth
vs. Year Ago Period: 92.00%
vs. Previous Quarter: 30.08%
ROE
02/28/22 - -38.11
11/30/21 - -33.83
08/31/21 - -29.81
ROA
02/28/22 - -28.14
11/30/21 - -24.88
08/31/21 - -22.04
Current Ratio
02/28/22 - 4.25
11/30/21 - 4.70
08/31/21 - 7.07
Quick Ratio
02/28/22 - 4.25
11/30/21 - 4.70
08/31/21 - 7.07
Operating Margin
02/28/22 - -394.21
11/30/21 - -393.93
08/31/21 - -342.27
Net Margin
02/28/22 - -394.21
11/30/21 - -393.93
08/31/21 - -342.27
Pre-Tax Margin
02/28/22 - -394.04
11/30/21 - -393.49
08/31/21 - -341.83
Book Value
02/28/22 - 6.82
11/30/21 - 7.67
08/31/21 - 8.45
Inventory Turnover
02/28/22 - -
11/30/21 - -
08/31/21 - -
Debt-to-Equity
02/28/22 - 0.00
11/30/21 - 0.00
08/31/21 - 0.00
Debt-to-Capital
02/28/22 - 0.00
11/30/21 - 0.00
08/31/21 - 0.00
 

Powered by Zacks Investment Research ©